Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Top Cited Papers
- 22 June 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (25), 3322-3331
- https://doi.org/10.1182/blood-2017-02-769208
Abstract
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.Keywords
This publication has 19 references indexed in Scilit:
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cellsScience Translational Medicine, 2016
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor ActivityCancer Immunology Research, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktailsCancer Immunology, Immunotherapy, 2012
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patientsJCI Insight, 2011